Lexaurin

Bromazepam, the active ingredient in Lexaurin, is a benzodiazepine presented as an oral dosage form for oral use. It acts on the central nervous system to produce anxiolytic effects and is prescribed for the short‑term relief of anxiety symptoms in adults.

GNH USA supplies Lexaurin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Bromazepam is used in the management of anxiety‑related disorders, providing rapid symptom control.

Anxiety disorders: reduces overall anxiety levels and improves patient comfort. Generalized anxiety disorder: offers short‑term relief of persistent worry and tension. Situational anxiety (e.g., before medical procedures): helps alleviate acute anxiety episodes.

Bromazepam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Drowsiness - Fatigue - Dizziness - Impaired coordination

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Paradoxical reactions such as agitation or aggression - Dependence and withdrawal seizures - Hepatic dysfunction

When prescribing bromazepam, clinicians should consider several safety precautions to minimise risk. - Pregnancy: avoid use unless clearly needed, as safety data are limited. - Elderly patients: start with the lowest dose and monitor for excessive sedation. - Concomitant alcohol: refrain from alcohol to prevent additive CNS depression. - Driving and machinery: advise patients to avoid operating vehicles until they know how the drug affects them. - Dependence: assess risk of tolerance and withdrawal with prolonged therapy. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Bromazepam can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - CNS depressants (e.g., opioids, barbiturates): may cause profound sedation or respiratory depression. - Alcohol: additive central nervous system depression leading to increased drowsiness. - Strong CYP3A4 inhibitors (e.g., ketoconazole, macrolide antibiotics): can raise bromazepam plasma concentrations.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Other benzodiazepines: increase cumulative sedative effect. - Selective serotonin reuptake inhibitors (SSRIs): may enhance sedation and dizziness.